Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VVOQM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RC88-Py-MAA-Val-Cit-PAB-MMAE
|
|||||
| Synonyms |
RC88-Py-MAA-Val-Cit-PAB-MMAE
Click to Show/Hide
|
|||||
| Organization |
REMEGEN, LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.95
|
|||||
| Structure |
|
|||||
| Antibody Name |
RC88
|
Antibody Info | ||||
| Antigen Name |
Mesothelin (MSLN)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
PY-MAA-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Py-MAA-Val-Cit-PAB-MMAE
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.093۪.009 nM | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
Oval-Citar-3-MSLN cells with good growth state were added to 96-well cell culture plates (5×104 cells /mL, 100uL/ well) and incubated overnight in a CO2 incubator at 37°C.
|
||||
| In Vitro Model | High grade ovarian serous adenocarcinoma | Oval-Citar-3-MSLN cells | CVCL_0465 | ||